---
kind: "section"
citation: "42 U.S.C. § 290ee–7"
title: "42"
title_heading: "The Public Health and Welfare"
number: "290ee–7"
heading: "Comprehensive opioid recovery centers"
release: "119-102"
date: "2026-07-12"
url: "https://uscodex.org/usc/42/290ee-7"
units:
  - "Chapter 6A — Public Health Service"
  - "Subchapter III–A — Substance Abuse and Mental Health Services Administration"
  - "Part D — Miscellaneous Provisions Relating to Substance Abuse and Mental Health"
---

# §290ee–7. Comprehensive opioid recovery centers

- (a) **In general—** The [Secretary](/usc/42/201.md?p=c) shall award grants on a competitive basis to eligible entities to establish or operate a comprehensive opioid recovery center (referred to in this section as a “Center”). A Center may be a single entity or an integrated delivery network.
- (b) **Grant period—**
  - (1) **In general—** A grant awarded under [subsection (a)](#a) shall be for a period of not less than 3 years and not more than 5 years.
  - (2) **Renewal—** A grant awarded under [subsection (a)](#a) may be renewed, on a competitive basis, for additional periods of time, as determined by the [Secretary](/usc/42/201.md?p=c). In determining whether to renew a grant under this paragraph, the [Secretary](/usc/42/201.md?p=c) shall consider the data submitted under [subsection (h)](#h).
- (c) **Minimum number of Centers—** The [Secretary](/usc/42/201.md?p=c) shall allocate the amounts made available under [subsection (j)](#j) such that not fewer than 10 grants may be awarded. Not more than one grant shall be made to entities in a single [State](/usc/42/201.md?p=f) for any one period.
- (d) **Application—**
  - (1) **Eligible entity—** An entity is eligible for a grant under this section if the entity offers [treatment](/usc/42/11851.md?p=11) and other [services](/usc/42/201.md?p=a) for individuals with a substance use disorder.
  - (2) **Submission of application—** In order to be eligible for a grant under [subsection (a)](#a), an entity shall submit an application to the [Secretary](/usc/42/201.md?p=c) at such time, in such manner, and containing such information and assurances, including relevant documentation, as the [Secretary](/usc/42/201.md?p=c) may require. Such application shall include—
    - (A) evidence that such entity carries out, or has the demonstrated capability to carry out, through referral or contractual arrangements, the activities described in [subsection (g)](#g); and
    - (B) such other information as the [Secretary](/usc/42/201.md?p=c) may require.
- (e) **Priority—** In awarding grants under [subsection (a)](#a), the [Secretary](/usc/42/201.md?p=c) shall give priority to eligible entities—
  - (1) located in a [State](/usc/42/201.md?p=f) with an age-adjusted rate of [drug](/usc/42/11851.md?p=4) overdose deaths that is above the national overdose mortality rate, as determined by the [Director](/usc/42/11851.md?p=5) of the Centers for Disease Control and Prevention; or
  - (2) serving an Indian Tribe (as defined in [section 5304 of title 25](/usc/25/5304.md)) with an age-adjusted rate of [drug](/usc/42/11851.md?p=4) overdose deaths that is above the national overdose mortality rate, as determined through appropriate mechanisms determined by the [Secretary](/usc/42/201.md?p=c) in consultation with Indian Tribes.
- (f) **Preference—** In awarding grants under [subsection (a)](#a), the [Secretary](/usc/42/201.md?p=c) may give preference to eligible entities utilizing technology-enabled collaborative learning and capacity building models, including such models as defined in [section 2](/usc/42/2.md) of the Expanding Capacity for Health Outcomes Act (Public Law 114–270; 130 Stat. 1395), to conduct the activities described in this section.
- (g) **Center activities—** Each Center shall, at a minimum, carry out the following activities directly, through referral, or through contractual arrangements, which may include carrying out such activities through technology-enabled collaborative learning and capacity building models described in [subsection (f)](#f):
  - (1) **Treatment and recovery services—** Each Center shall—
    - (A) Ensure that intake, evaluations, and periodic patient assessments meet the individualized clinical needs of patients, including by reviewing patient [placement](/usc/42/300gg–91.md?p=d-12) in [treatment](/usc/42/11851.md?p=11) settings to support meaningful recovery.
    - (B) Provide the full continuum of [treatment](/usc/42/11851.md?p=11) [services](/usc/42/201.md?p=a), including—
      - (i) all [drugs](/usc/42/11851.md?p=4) and devices approved or cleared under the Federal Food, [Drug](/usc/42/11851.md?p=4), and Cosmetic Act and all biological products licensed under [section 262 of this title](/usc/42/262.md) to treat substance use disorders or reverse overdoses, pursuant to Federal and [State](/usc/42/201.md?p=f) law;
      - (ii) medically supervised withdrawal management, that includes patient evaluation, stabilization, and readiness for and entry into [treatment](/usc/42/11851.md?p=11);
      - (iii) counseling provided by a [program](/usc/42/274l–1.md?p=4) counselor or other certified professional who is licensed and qualified by education, training, or experience to assess the psychological and sociological background of patients, to contribute to the appropriate [treatment](/usc/42/11851.md?p=11) plan for the patient, and to monitor patient progress;
      - (iv) [treatment](/usc/42/11851.md?p=11), as appropriate, for patients with co-occurring substance use and mental disorders;
      - (v) testing, as appropriate, for infections commonly associated with [illicit](/usc/42/11851.md?p=6) [drug](/usc/42/11851.md?p=4) use;
      - (vi) residential rehabilitation, and outpatient and intensive outpatient [programs](/usc/42/274l–1.md?p=4);
      - (vii) recovery housing;
      - (viii) community-based and peer recovery support [services](/usc/42/201.md?p=a);
      - (ix) job training, job [placement](/usc/42/300gg–91.md?p=d-12) assistance, and continuing education assistance to support reintegration into the workforce; and
      - (x) other best [practices](/usc/42/17061.md?p=19) to provide the full continuum of [treatment](/usc/42/11851.md?p=11) and [services](/usc/42/201.md?p=a), as determined by the [Secretary](/usc/42/201.md?p=c).
    - (C) Ensure that all [programs](/usc/42/274l–1.md?p=4) covered by the Center include medication-assisted [treatment](/usc/42/11851.md?p=11), as appropriate, and do not exclude individuals receiving medication-assisted [treatment](/usc/42/11851.md?p=11) from any [service](/usc/42/201.md?p=a).
    - (D) Periodically conduct patient assessments to support sustained and clinically significant recovery, as defined by the Assistant [Secretary](/usc/42/201.md?p=c) for Mental Health and Substance Use.
    - (E) Provide onsite access to medication, as appropriate, and toxicology [services](/usc/42/201.md?p=a); for purposes of carrying out this section.
    - (F) Operate a secure, confidential, and interoperable electronic health information system.
    - (G) Offer family support [services](/usc/42/201.md?p=a) such as child care, family counseling, and parenting interventions to help stabilize families impacted by substance use disorder, as appropriate.
  - (2) **Outreach—** Each Center shall carry out outreach activities regarding the [services](/usc/42/201.md?p=a) offered through the Centers, which may include—
    - (A) training and supervising outreach staff, as appropriate, to work with [State](/usc/42/201.md?p=f) and local health departments, [health care providers](/usc/42/300aa–33.md?p=1), the Indian Health [Service](/usc/42/201.md?p=a), [State](/usc/42/201.md?p=f) and [local educational agencies](/usc/42/300j–21.md?p=3), [schools](/usc/42/300j–21.md?p=6) funded by the Indian Bureau of Education, institutions of higher education, [State](/usc/42/201.md?p=f) and local workforce development boards, [State](/usc/42/201.md?p=f) and local community action [agencies](/usc/42/8262.md?p=1), public safety officials, first responders, Indian Tribes, child welfare [agencies](/usc/42/8262.md?p=1), as appropriate, and other community partners and the public, including patients, to identify and respond to community needs;
    - (B) ensuring that the entities described in [subparagraph (A)](#g-2-A) are aware of the [services](/usc/42/201.md?p=a) of the Center; and
    - (C) disseminating and making publicly available, including through the internet, evidence-based resources that educate professionals and the public on opioid use disorder and other substance use disorders, including co-occurring substance use and mental disorders.
- (h) **Data reporting and program oversight—**
  - (1) **In general—** With respect to a grant awarded under [subsection (a)](#a), not later than 90 days after the end of the first year of the grant period, and annually thereafter for the duration of the grant period (including the duration of any renewal period for such grant), the entity shall submit data, as appropriate, to the [Secretary](/usc/42/201.md?p=c) regarding—
    - (A) the [programs](/usc/42/274l–1.md?p=4) and activities funded by the grant;
    - (B) health outcomes of the population of individuals with a substance use disorder who received [services](/usc/42/201.md?p=a) from the Center, evaluated by an independent [program](/usc/42/274l–1.md?p=4) evaluator through the use of outcomes measures, as determined by the [Secretary](/usc/42/201.md?p=c);
    - (C) the retention rate of [program](/usc/42/274l–1.md?p=4) [participants](/usc/42/300gg–91.md?p=d-11); and
    - (D) any other information that the [Secretary](/usc/42/201.md?p=c) may require for the purpose of—ensuring[^1] that the Center is complying with all the requirements of the grant, including providing the full continuum of [services](/usc/42/201.md?p=a) described in [subsection (g)(1)(B)](#g-1-B).
  - (2) **Additional reporting for certain eligible entities—** An entity carrying out activities described in [subsection (g)](#g) through referral or contractual arrangements shall include in the submissions required under [paragraph (1)](#h-1) information related to the status of such referrals or contractual arrangements, including an assessment of whether such referrals or contractual arrangements are supporting the ability of such entity to carry out such activities.
- (i) **Privacy—** The provisions of this section, including with respect to data reporting and [program](/usc/42/274l–1.md?p=4) oversight, shall be subject to all applicable Federal and [State](/usc/42/201.md?p=f) privacy laws.
- (j) **Authorization of appropriations—** There is authorized to be appropriated $10,000,000 for each of fiscal years 2026 through 2030 for purposes of carrying out this section.

## Footnotes

[^1]: So in original.

## Source credit

(July 1, 1944, ch. 373, title V, § 552, as added Pub. L. 115–271, title VII, § 7121(a), Oct. 24, 2018, 132 Stat. 4043; amended Pub. L. 119–44, title III, § 303, Dec. 1, 2025, 139 Stat. 685.)

## Notes

### Editorial Notes

### References in Text

Section 2 of the Expanding Capacity for Health Outcomes Act, referred to in subsec. (f), is section 2 of Pub. L. 114–270, Dec. 14, 2016, 130 Stat. 1395, which is not classified to the Code.

The Federal Food, Drug, and Cosmetic Act, referred to in subsec. (g)(1)(B)(i), is act June 25, 1938, ch. 675, 52 Stat. 1040, which is classified generally to chapter 9 (§ 301 et seq.) of Title 21, Food and Drugs. For complete classification of this Act to the Code, see section 301 of Title 21 and Tables.

### Amendments

2025—Subsec. (d)(2). Pub. L. 119–44, § 303(1)(A), substituted “, in such manner, and containing such information and assurances, including relevant documentation,” for “and in such manner” in introductory provisions.

Subsec. (d)(2)(A). Pub. L. 119–44, § 303(1)(B), substituted “has the demonstrated capability to carry out, through referral or contractual arrangements” for “is capable of coordinating with other entities to carry out”.

Subsec. (h). Pub. L. 119–44, § 303(2), designated existing provisions as par. (1), inserted heading, redesignated former pars. (1) to (4) as subpars. (A) to (D), respectively, of par. (1) and realigned margins, and added par. (2).

Subsec. (j). Pub. L. 119–44, § 303(3), substituted “2026 through 2030” for “2019 through 2023”.